Nicholas Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Nicholas Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,800	Closed	-$887K	–	206
2016 Q1	$887K	Sell	6,800 -668,430	-99%	-$83.2M	0.02%	192
2015 Q4	$94.9M	Buy	675,230 +241,605	+56%	+$33.5M	1.78%	23
2015 Q3	$57.6M	Buy	433,625 +48,200	+13%	+$8.3M	1.09%	38
2015 Q2	$67.9M	Buy	385,425 +336,280	+684%	+$60.4M	1.19%	34
2015 Q1	$8.49M	Buy	49,145 +1,100	+2%	+$189K	0.16%	106
2014 Q4	$7.87M	Hold	48,045	–	–	0.16%	110
2014 Q3	$7.71M	Buy	48,045 +10,010	+26%	+$1.54M	0.18%	109
2014 Q2	$5.59M	Buy	38,035 +2,500	+7%	+$347K	0.13%	126
2014 Q1	$4.93M	Sell	35,535 -14,515	-29%	-$2.18M	0.12%	135
2013 Q4	$6.33M	Hold	50,050	–	–	0.15%	128
2013 Q3	$4.6M	Buy	+50,050	New	+$4.04M	0.12%	139

Other funds holding JAZZ

PRCM

Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Nicholas Company's JAZZ Position: Q2 2016 in Review

Nicholas Company sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2016, closing a stake of 6,800 shares — an estimated $887K sold.

Nicholas Company first reported a position in JAZZ in Q3 2013 and held it in 11 quarters. The position peaked at $94.9M in Q4 2015. 367 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

Nicholas Company reported no remaining Jazz Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Nicholas Company sold 6,800 Jazz Pharmaceuticals shares in Q2 2016, an estimated $887K.
Nicholas Company first reported a position in Jazz Pharmaceuticals in Q3 2013 and held it in 11 quarters.
Nicholas Company's Jazz Pharmaceuticals position peaked at $94.9M in Q4 2015.
367 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on Nicholas Company's 13F filing for Q2 2016, filed 12 Aug 2016.